Compare Moderna, Inc. (MRNA) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs NICE Ltd — how do they compare? Moderna, Inc. trades at $197.52 (market cap $78.44B), while NICE Ltd trades at $117 (market cap $6.83B). The key difference: Moderna, Inc. is far larger — about 11.5× NICE Ltd's market cap, and Moderna, Inc. is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and NICE Ltd for 15 Days on average.
| MRNA | NICE | |
|---|---|---|
Market Cap | $78.44B | $6.83B |
Volume | 14,597,511 | 444,610 |
Sector | Health | Technology |
52-Week High | $203.46 | $137.68 |
52-Week Low | $22.36 | $83.15 |
Typical Hold Time | 59 Days | 15 Days |
Enterprise Value | $74.59B | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
NICE (NICE) trades at $116.42, up 0.95% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $2.95 billion in 2025, though net income is projected to decline in 2026. Recent news highlights leadership in AI-driven contact center platforms and positive institutional buying interest.
The outlook for NICE is positive, supported by AI revenue growth and a reasonable valuation, but investors face risks from margin compression and earnings volatility. The stock's proximity to resistance at $118 suggests near-term consolidation may occur before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
